MediciNova, Inc.

NasdaqGM:MNOV 株式レポート

時価総額:US$76.5m

MediciNova 過去の業績

過去 基準チェック /06

MediciNovaは5.4%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで19%毎年増加している。売上は成長しており、年平均5.5%の割合である。

主要情報

5.4%

収益成長率

8.9%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率5.5%
株主資本利益率-14.2%
ネット・マージン-816.5%
次回の業績アップデート14 Nov 2024

最近の業績更新

Recent updates

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Aug 28
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Apr 19
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Nov 27
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Jul 11
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

Mar 18
Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

Oct 12
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

MediciNova to get US patent for MN-166 to treat brain cancer

Sep 15

MediciNova's MN-166 to be part of study to treat Long COVID

Aug 16

MediciNova begins study of parenteral formulation of MN-166

Jul 22

MediciNova announces extension of BARDA contract for Ibudilast development

Jun 30

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Mar 19
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

Nov 23
MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

MediciNova: The Pain Of A Positive Outlook

Aug 31

MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study

Jun 21

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

May 15
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

The MediciNova Riddle: Worth Unravelling

Apr 26

MediciNova inks $20M securities purchase agreement with 3D Investment Partners

Jan 12

MediciNova nabs new U.S. patent for ibudilast in multiple sclerosis

Dec 29

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Dec 29
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

収支内訳

MediciNova の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGM:MNOV 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 241-856
31 Mar 241-856
31 Dec 231-956
30 Sep 231-1066
30 Jun 230-1268
31 Mar 230-1469
31 Dec 220-1459
30 Sep 220-1359
30 Jun 220-1359
31 Mar 220-1359
31 Dec 214-1069
30 Sep 214-1179
30 Jun 214-1179
31 Mar 214-1178
31 Dec 200-1477
30 Sep 200-1368
30 Jun 200-1266
31 Mar 200-1166
31 Dec 190-1386
30 Sep 190-1184
30 Jun 190-16116
31 Mar 190-15106
31 Dec 180-15106
30 Sep 180-16127
30 Jun 180-13105
31 Mar 180-13105
31 Dec 170-1194
30 Sep 170-1174
30 Jun 170-1073
31 Mar 170-1173
31 Dec 160-1173
30 Sep 160-1284
30 Jun 160-1174
31 Mar 160-1073
31 Dec 150-963
30 Sep 150-863
30 Jun 150-963
31 Mar 150-963
31 Dec 140-963
30 Sep 146-363
30 Jun 146-363
31 Mar 146-473
31 Dec 136-473

質の高い収益: MNOVは現在利益が出ていません。

利益率の向上: MNOVは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: MNOVは利益を出していないが、過去 5 年間で年間5.4%の割合で損失を削減してきた。

成長の加速: MNOVの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: MNOVは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 13.6% ) と比較することは困難です。


株主資本利益率

高いROE: MNOVは現在利益が出ていないため、自己資本利益率 ( -14.22% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘